Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene

NCT06291935 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinitis Pigmentosa

Interventions

DRUG: VG901

Sponsor

VeonGen Therapeutics GmbH